Current Report Filing (8-k)
May 12 2017 - 4:24PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
May 11, 2017
Date of
report (Date of earliest event reported)
Nexvet
Biopharma
public limited company
(Exact Name of Registrant as Specified in Its Charter)
|
|
|
|
|
|
|
Ireland
|
|
001-36828
|
|
98-1205017
|
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification Number)
|
Unit 5, Sragh Technology Park
Rahan Road, Tullamore
Co. Offaly, R35 FR98, Ireland
(Address of principal executive offices, including zip code)
+353 5793 24522
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form
8-K
filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions:
|
|
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
☒
|
Soliciting material pursuant to Rule
14a-12
under the Exchange Act (17 CFR
240.14a-12)
|
|
|
☐
|
Pre-commencement
communications pursuant to Rule
14d-2(b)
under the Exchange Act (17 CFR
240.14d-2(b))
|
|
|
☐
|
Pre-commencement
communications pursuant to Rule
13e-4(c)
under the Exchange Act (17 CFR
240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as
defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule
12b-2
of the Securities Exchange Act of 1934 (17 CFR
§240.12b-2).
|
|
|
|
|
|
|
|
|
Emerging growth company
|
|
☒
|
|
|
|
|
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
On May 11, 2017, Nexvet Biopharma plc, a public limited company
incorporated in Ireland (the “
Company
”), issued an announcement (the “
Rule
2.10
Announcement
”) pursuant to Rule 2.10 of the Irish Takeover Panel Act, 1997, Takeover Rules
2013, regarding the Company’s issued share capital. A copy of the Rule 2.10 Announcement is attached hereto as Exhibit 99.1 and incorporated by reference herein.
|
Item 9.01.
|
Financial Statements and Exhibits.
|
(d) Exhibits.
|
|
|
|
|
Exhibit
No.
|
|
Description
|
|
|
|
|
99.1
|
|
Rule 2.10 Announcement, dated May 11, 2017.
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
|
|
|
|
|
|
|
|
Date: May 12, 2017
|
|
|
|
NEXVET BIOPHARMA PUBLIC LIMITED COMPANY
|
|
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ Mark Heffernan, Ph.D.
|
|
|
|
|
|
Name:
|
|
Mark Heffernan
|
|
|
|
|
|
Title:
|
|
Chief Executive Officer
|
EXHIBIT INDEX
|
|
|
|
|
Exhibit
No.
|
|
Description
|
|
|
|
|
99.1
|
|
Rule 2.10 Announcement, dated May 11, 2017.
|
NEXVET BIOPHARMA PLC (NASDAQ:NVET)
Historical Stock Chart
From Mar 2024 to Apr 2024
NEXVET BIOPHARMA PLC (NASDAQ:NVET)
Historical Stock Chart
From Apr 2023 to Apr 2024
